All In Biotech

Drug Trial Radar · NCT00421109

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria

Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 522 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

522

Actual

Start

Jul 2006

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
First posted
Jan 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.

Conditions

  • Urticaria

Interventions

  • BilastineDrug

    Encapsulated 20 mg Tablet. Once daily for 28 days

  • LevocetirizineDrug

    Encapsulated 5 mg tablet. Once daily for 28 days

  • PlaceboDrug

    Encapsulated tablet. Once daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline, in the am/pm Total Symptom Score (TSS3), over the 28 days of the treatment period according to the patient's assessment in the diary card. (Reflective Symptoms)Time frame: 28 days

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • Centre nº 101

    Buenos Aires, Argentina

  • Centre nº 105

    Buenos Aires, Argentina

  • Centre nº 104

    Buenos Aires, Argentina

  • Centre nº 103

    Buenos Aires, Argentina

  • Centre nº 107

    Buenos Aires, Argentina

  • Centre nº 109

    Buenos Aires, Argentina

  • Centre nº 108

    Buenos Aires, Argentina

  • Centre nº 100

    Mar Del Plata / Buenos Aires, Argentina

  • Centre nº 106

    Rosario - Santa Fe, Argentina

  • Centre nº 102

    Salta, Argentina

  • Centre nº 202

    Aalst, Belgium

  • Centre nº 200

    Edegem, Belgium

  • Centre nº 201

    Ghent, Belgium

  • Centre nº 204

    Ghent, Belgium

  • Centre nº 203

    Kortrijk, Belgium

  • Centre nº 302

    Lyon, France

  • Centre nº 305

    Marseille, France

  • Centre nº 307

    Nice, France

  • Centre nº 303

    Paris, France

  • Centre nº 308

    Quimper, France

  • Centre nº 301

    Reims, France

  • Centre nº 411

    Berlin, Germany

  • Centre nº 404

    Berlin, Germany

  • Centre nº 410

    Berlin, Germany

  • Centre nº 400

    Hamburg, Germany

  • Centre nº 407

    Hanover, Germany

  • Centre nº 406

    Leipzig, Germany

  • Centre nº 505

    Iwonicz-Zdrój, Poland

  • Centre nº 507

    Krakow, Poland

  • Centre nº 503

    Krakow, Poland

  • Centre nº 504

    Lodz, Poland

  • Centre nº 502

    Lublin, Poland

  • Centre nº 506

    Poznan, Poland

  • Centre nº 501

    Warsaw, Poland

  • Centre nº 500

    Wroclaw, Poland

  • Centre nº 704

    Brasov, Romania

  • Centre nº 700

    Bucharest, Romania

  • Centre nº 701

    Bucharest, Romania

  • Centre nº 702

    Bucharest, Romania

  • Centre nº 705

    Bucharest, Romania

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.